Inogen reported second quarter 2026 revenue of $95.1 million, a 3.0% increase year-over-year, driven by international demand and foreign exchange benefits. The company posted a GAAP net loss of $3.9 million compared to $4.2 million in the prior year period, while adjusted EBITDA rose 15.2% to $2.4 million. Management raised full-year 2026 adjusted EBITDA guidance to approximately $4.0 million and updated revenue expectations to a range of $355 million to $361 million. Operational highlights include the launch of the Rove 6 portable oxygen concentrator in Canada, completion of enrollment for the Simeox H SCOPE Study in China, and the appointment of Andy Reding as Chief Operating Officer. The company operates in the medical technology industry, developing and marketing innovative respiratory therapy devices for homecare settings.

Inogen, Inc. appointed Andrew (Andy) Reding to serve as Executive Vice President and Chief Operating Officer, effective July 6, 2026. Mr. Reding's compensation package includes a $500,000 annual base salary, a 70% target annual performance bonus, a $100,000 sign-on bonus, and an award of 130,000 time-based restricted stock units. Inogen, Inc. is a medical device company that provides oxygen concentrator technology for home use.

At its annual meeting on June 5, 2026, Inogen, Inc. stockholders approved the Amended and Restated 2023 Equity Incentive Plan, which increases the number of common shares available for issuance by 750,000. Shareholders also elected Glenn Boehnlein and Mira Sahney as Class III directors and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the 2026 fiscal year. An advisory vote on executive compensation was approved, but a proposal to declassify the Board of Directors failed to pass. Inogen, Inc. develops and markets portable oxygen concentrators for medical use.